Plasma Biomarkers Market

Global Plasma Biomarkers Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2023-2029- The market will expand due to the increasing prevalence of chronic diseases, technological advancements, and growing demand for personalized medicine.

Global Plasma Biomarkers Market is valued at USD 6.09 Billion in 2022 and it is expected to reach USD 13.98 Billion by 2029 with a CAGR of 12.6% over the forecast period.

Scope of Global Plasma Biomarkers Market Report-

The plasma biomarkers market refers to the market for biomarkers that are found in plasma, which is the liquid component of blood. Biomarkers are molecules that are indicative of a specific biological state or condition, and these can be used to diagnose or monitor diseases, evaluate the efficacy of treatments, and predict disease outcomes.

The history of plasma biomarkers can be traced back to the discovery of proteins such as albumin and globulin in blood in the 19^th century. Over time, advances in technology have allowed for the identification and measurement of a wide range of biomolecules in plasma, including enzymes, hormones, and nucleic acids.

The application of plasma biomarkers is widespread, with uses in fields such as oncology, neurology, cardiology, and infectious disease. For example; plasma biomarkers such as PSA (prostate-specific antigen) and CA-125 (cancer antigen 125) are used in the diagnosis and monitoring of prostate and ovarian cancer, respectively. In neurology, plasma biomarkers such as plasma neurofilament light (NFL) are being studied as potential markers of neurodegenerative diseases like Alzheimer's disease. The end users of plasma biomarkers include hospitals and clinics, research institutions, and diagnostic laboratories.

Plasma biomarkers for Alzheimer's disease are also an active area of research. Biomarkers such as amyloid-beta and tau proteins in plasma may be indicative of the pathological processes underlying Alzheimer's disease, and measuring these biomarkers may allow for earlier detection and better tracking of disease progression.

Revenue Generation Model:

The revenue generation model for the plasma biomarkers market is primarily based on the sales of diagnostic tests and research tools that utilize plasma biomarkers. Diagnostic tests that measure specific plasma biomarkers, such as PSA for prostate cancer or amyloid-beta for Alzheimer's disease, can be sold to healthcare providers and diagnostic laboratories. Research tools, such as immunoassays and mass spectrometry systems, that enable the measurement and analysis of plasma biomarkers can be sold to research institutions and pharmaceutical companies.

Supply Chain Analysis:

The supply chain model for the plasma biomarkers market involves several key stakeholders, including biomarker discovery companies, diagnostic test manufacturers, and research tool providers. Biomarker discovery companies identify and validate new plasma biomarkers, which are then licensed or sold to diagnostic test manufacturers and research tool providers. Diagnostic test manufacturers and research tool providers then develop and commercialize products that utilize these biomarkers, which are distributed through healthcare providers, diagnostic laboratories, and research institutions.

Value Chain Analysis:

The value chain model for the plasma biomarkers market involves several key stages, including biomarker discovery, biomarker validation, product development, and commercialization. Biomarker discovery involves identifying and characterizing potential plasma biomarkers through methods such as proteomics and genomics. Biomarker validation involves demonstrating the clinical utility and reliability of plasma biomarkers through clinical studies and regulatory approval. Product development involves designing and manufacturing diagnostic tests and research tools that utilize plasma biomarkers. Commercialization involves marketing and distributing these products to end-users such as healthcare providers, diagnostic laboratories, and research institutions.

Covid-19 Impact on the Global Plasma Biomarkers Market:

The Covid-19 pandemic has had a mixed impact on the plasma biomarkers market. On one hand, the pandemic has led to an increased demand for diagnostic tests that can rapidly and accurately detect Covid-19 infection. Many companies have developed diagnostic tests that utilize plasma biomarkers, such as antibodies or antigens, as a means of detecting the virus. This has led to a surge in demand for plasma biomarker-based diagnostic tests, which has driven market growth.

On the other hand, the pandemic has also disrupted supply chains and manufacturing processes, leading to delays and shortages in the production of plasma biomarker-based diagnostic tests and research tools. Furthermore, the pandemic has forced many clinical trials and research studies involving plasma biomarkers to be postponed or canceled, leading to a decline in market growth.

In addition, the Covid-19 pandemic has also led to a shift in research priorities, with many researchers and companies focusing their efforts on developing biomarkers and diagnostic tests for COVID-19. This has led to a temporary slowdown in research and development efforts related to other diseases and conditions that can be diagnosed using plasma biomarkers.

Key Players of Global Plasma Biomarkers Market Report-

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers
• Abbott Laboratories
• QIAGEN N.V.
• BioMérieux SA
• Merck KGaA
• Agilent Technologies Inc.
• Danaher Corporation
• Becton
• Dickinson and Company
• Myriad Genetics Inc.
• Luminex Corporation
• Illumina Inc.
• Bruker Corporation
• Waters Corporation
• Randox Laboratories Ltd.
• Abcam plc
• Natera Inc.
• Proteome Sciences plc
• Biodesix Inc.
• Vermillion Inc.
• Pacific Biomarkers
• Singulex Inc.
• ThermoGenesis Holdings Inc.
• SomaLogic Inc.
• Aushon BioSystems Inc.
• HealthTell Inc.
• Enzo Biochem Inc.
• Rules-Based Medicine Inc.

Global Plasma Biomarkers Market Segmentation:-

By Product:

• Protein Biomarkers
• Glycoprotein Biomarkers
• Nucleic Acid Biomarkers
• Small Molecule Biomarkers
• Others

By Disease Indication:

• Cancer
• Cardiovascular Diseases
• Neurological Disorders
• Immunological Disorders
• Respiratory disorders
• Infectious diseases
• Others

By Technology:

• Immunoassay
• Mass Spectrometry
• ELISA
• Omics
• Others

By Application:

• Diagnostics
• Drug Discovery and Development
• Personalized Medicine
• Others

By End-User:

• Hospitals and Clinics
• Diagnostic Centers
• Research Laboratories and Institutes

By Regional & Country Level:

• North America
  • S.
  • Canada
• Europe
  • K.
  • France
  • Germany
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Market Drivers:

Increasing prevalence of chronic diseases: The increasing prevalence of chronic diseases such as cancer, cardiovascular disease, and neurological disorders is a driving factor in the plasma biomarkers market. For example; in 2020, as many as 5.8 million Americans 65 years and older had Alzheimer’s disease, and the prevalence in the United States is projected to increase to 13.8 million by 2050. The growing incidence of these diseases has led to an increase in demand for non-invasive and personalized diagnostic tools that can accurately and quickly diagnose and monitor disease progression.

The use of plasma biomarkers in the development of these diagnostic tools is critical, as they can provide valuable insights into disease mechanisms and help predict patient outcomes. Therefore, there is a need for continued investment in research and development of plasma biomarkers to address the growing demand for personalized medicine.

For instance; personalized medicines accounted for more than one-third of new drug approvals for 4 of the past 5 years. In 2021, of the 48 new therapeutic molecular therapies approved by the FDA’s Center for Drug Evaluation and Research, 17 were approved as personalized medicines, which represented an estimated 35% of all newly approved therapeutic molecular entities

Technological advancements are a driving factor in the plasma biomarkers market: Advances in high-throughput sequencing, proteomics, and metabolomics have enabled researchers to identify new biomarkers with greater sensitivity and specificity. This, in turn, has led to the development of more accurate and personalized diagnostic tests, which can detect diseases earlier and improve patient outcomes.

Furthermore, the development of point-of-care testing (POCT) devices has made biomarker analysis more accessible, affordable, and rapid. As a result, there is a growing demand for POCT devices that can quickly and accurately diagnose diseases in low-resource settings. For example; the CDC has distributed more than 300,000 Covid-19 rapid antigen tests to nursing homes and other long-term care facilities in the United States, demonstrating the growing use of POCT devices in the management of infectious diseases.

Market Restraints:

One of the main restraining factors for the adoption of plasma biomarkers and other diagnostic technologies is competition from alternative technologies. For example; traditional laboratory-based testing methods, such as ELISA assays and Western blotting, are still widely used in many settings and may be preferred by some healthcare providers.

In addition, newer technologies such as genomics and transcriptomics may also provide valuable diagnostic information and compete with plasma biomarkers for market share. Another challenge is the development of high-quality, reliable, and cost-effective POCT devices that can compete with traditional laboratory-based methods. This competition can limit the growth and adoption of plasma biomarkers and other diagnostic technologies and may require further investment in research and development to stay ahead of the curve.

Market Opportunities:

Rising demand for non-invasive diagnostic tests: Non-invasive diagnostic tests, such as those that use blood or urine samples, are becoming more popular as they are less invasive and more convenient for patients. This trend is expected to continue, and the global non-invasive diagnostics market is projected to reach $29.3 billion by 2026, according to a report by Meticulous Research. As plasma biomarkers are a non-invasive diagnostic test, this market trend could present significant growth opportunities.

Increasing investment in research and development: The plasma biomarkers industry is seeing increasing investment in research and development, which is driving innovation and leading to the development of new biomarkers.

Market Trend:

Product and Technology Development Trends:

Some of the major trends of the global plasma biomarkers market are increasing focus on developing multi-biomarker panels for more accurate disease diagnosis and monitoring, growing adoption of next-generation sequencing (NGS), advancements in point-of-care testing (POCT) devices for real-time biomarker measurement, development of liquid biopsy tests that use plasma biomarkers for cancer diagnosis and monitoring, and the growing use of machine learning and artificial intelligence (AI) for data analysis and biomarker discovery.

Customer Trends:

Increasing demand for personalized medicine and targeted therapies based on plasma biomarker analysis, growing awareness among patients and healthcare providers about the potential benefits of plasma biomarker-based testing, increasing adoption of plasma biomarker testing in clinical research and drug development, growing interest in non-invasive and less expensive biomarker testing methods, such as liquid biopsy tests, and increasing emphasis on preventive healthcare and early disease detection using plasma biomarkers.

Market Competition Nature:

Competition in the plasma biomarkers market is intense, with a large number of companies operating in the space. Key players in the market include F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., and Abbott Laboratories, among others. These companies compete on the basis of product quality, pricing, distribution network, and technological advancements.

In order to stay competitive, key market players are adopting various strategies such as mergers and acquisitions, partnerships and collaborations, and product launches. For example, in 2021, Thermo Fisher Scientific acquired Mesa Biotech, Inc. to expand its capabilities in point-of-care testing. In 2020, F. Hoffmann-La Roche AG launched a new Elecsys Tau CSF test for the diagnosis of Alzheimer's disease. These strategies are aimed at expanding market share and improving product portfolios to meet the growing demand for plasma biomarkers.

Additionally, some companies are also investing in research and development to innovate new products and technologies to stay ahead of the competition. For example, Bio-Rad Laboratories, Inc. invested $84.1 million in research and development activities in 2020. These efforts are expected to result in the development of novel plasma biomarker tests that can offer improved accuracy and efficiency, thereby providing a competitive advantage to market players.

Geography Analysis:

North America:

The North America is expecetd to show a significant growth in the global plasma biomarkers market. Geographically, The North America region is a significant market for plasma biomarkers, with the presence of key market players, increasing investments in research and development, and high adoption of advanced technologies. The region has a well-established healthcare infrastructure, which has led to a higher demand for advanced diagnostic tools and personalized medicines, driving the growth of the plasma biomarkers market. According to a survey by the Personalized Medicine Coalition, 42% of new drugs approved by the FDA in 2020 had a personalized medicine component, up from 25% in 2015.

Furthermore, the increasing prevalence of chronic diseases, such as cancer, Alzheimer's disease, and cardiovascular diseases, is also driving the demand for plasma biomarkers in the North American market. For example; according to the Alzheimer's Association, there are currently an estimated 6.2 million people living with Alzheimer's disease in the United States. The use of plasma biomarkers in the early diagnosis and treatment of these diseases is expected to drive the growth of the market in the region.

Europe:

The Europe market is highly competitive, with several key players operating in the region. The growth is attributed to the increasing prevalence of chronic diseases, the aging population, and the availability of advanced healthcare infrastructure. Some of the prominent countries in this region, such as Germany, the UK, and France, have a large patient population base, which further drives the growth of the plasma biomarkers market.

For example; according to NIH, in EU-27, the estimated new cancer cases are approximately 1.4 million in males and 1.2 million in females, with over 710,000 estimated cancer deaths in males and 560,000 in females. This highlights the need for biomarker-based cancer diagnosis and treatment in the region.

In addition, this region is witnessing an increasing trend toward personalized medicine, which involves the use of biomarkers to identify the patient’s response to treatment and potential side effects. This trend is expected to create a significant demand for plasma biomarkers, driving market growth.

Key Benefits of Global Plasma Biomarkers Market Report–

• Global Plasma Biomarkers Market report covers in-depth historical and forecast analysis.
• Global Plasma Biomarkers Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country Level.
• Global Plasma Biomarkers Market report helps to identify opportunities in the marketplace.
• Global Plasma Biomarkers Market report covers extensive analysis of emerging trends and competitive landscape.